James Treco Net Worth

The estimated Net Worth of James Treco is at least $1.5 Thousand dollars as of 31 August 2020. Mr. Treco owns over 5,500 units of Tonix Pharmaceuticals Corp stock worth over $1,500 and over the last 6 years he sold TNXP stock worth over $0. In addition, he makes $0 as Lead Independent Director at Tonix Pharmaceuticals Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Treco TNXP stock SEC Form 4 insiders trading

James has made over 2 trades of the Tonix Pharmaceuticals Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,500 units of TNXP stock worth $4,895 on 31 August 2020.

The largest trade he's ever made was buying 5,500 units of Tonix Pharmaceuticals Corp stock on 31 August 2020 worth over $4,895. On average, James trades about 1,000 units every 2 days since 2019. As of 31 August 2020 he still owns at least 10,000 units of Tonix Pharmaceuticals Corp stock.

You can see the complete history of Mr. Treco stock trades at the bottom of the page.

James Treco biography

James Treco serves as Lead Independent Director of the Company. He became a director in February 2019. Mr. Treco has been a Managing Partner at First Chicago Advisors, Inc., a boutique financial advisory firm where he advises executives and boards of directors of a wide range of companies, from global, large-cap companies to emerging companies, from 2009 to 2012 and from 2014 to the present. From 2012 to 2013 Mr. Treco was an investment banker with Gleacher & Company, a company that previously operated an investment banking business, providing corporate and institutional clients with strategic and financial advisory services. Mr. Treco held various positions of increasing responsibility at Salomon Brothers/Citigroup from 1984 to 2008, where he used his extensive experience in the global capital markets to advise a wide range of clients. Mr. Treco holds a B.A. from Yale University and an M.B.A. from the Stanford University Graduate School of Business. Mr. Treco’s extensive healthcare and investment banking experience were instrumental in his selection as a member of the Board.

How old is James Treco?

James Treco is 64, he's been the Lead Independent Director of Tonix Pharmaceuticals Corp since 2020. There are 3 older and 12 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.

What's James Treco's mailing address?

James's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN STREET, SUITE 101, CHATHAM, NJ, 07928.

Insiders trading at Tonix Pharmaceuticals Corp

Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman, and Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.

What does Tonix Pharmaceuticals Corp do?

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

Complete history of Mr. Treco stock trades at Tonix Pharmaceuticals Corp

Tonix Pharmaceuticals Corp executives and stock owners

Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Seth Lederman,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Seth Lederman M.D.,
  Co-Founder, Pres, CEO & Chairman
• Dr. Seth Lederman,
  Co-Founder, Pres, CEO & Chairman
• Dr. Gregory M. Sullivan M.D.,
  Chief Medical Officer & Sec.
• Gregory Sullivan,
  Secretary, Chief Medical Officer
• Bradley Saenger CPA, CPA,
  CFO & Treasurer
• Bradley Saenger,
  Chief Financial Officer, Treasurer
• Richard Bagger,
  Director
• Herbert Harris,
  Executive Vice President - Translational Medicine
• David Grange,
  Independent Director
• Margaret Bell,
  Independent Director
• James Treco,
  Lead Independent Director
• Adeoye Olukotun,
  Independent Director
• Daniel Goodman,
  Independent Director
• Jessica Morris,
  Chief Operating Officer
• Dr. Sina Bavari Ph.D.,
  Exec. VP of Infectious Disease R&D
• Dr. Anthony Macaluso Ph.D.,
  Exec. VP of Strategic Devel.
• Dr. Darryl Rideout Ph.D.,
  Exec. VP of Experimental Chemistry
• Siobhan Fogarty B.Sc., M.Sc.,
  Exec. VP of Product Devel.
• Dr. Bruce L. Daugherty M.B.A., Ph.D.,
  Exec. VP of Research
• Dr. Herbert W. Harris M.D., Ph.D.,
  Exec. VP of Translational Medicine
• Dr. R. Michael Gendreau,
  Consultant
• Dr. Daniel J. Clauw M.D.,
  Consultant
• Dr. Ronald R. Notvest,
  Exec. VP of Commercial Planning and Devel.
• Jessica Edgar Morris,
  Chief Operating Officer
• Charles E Iv Mather,
  Director
• Ernest Mario,
  Director
• John B Rhodes,
  Director
• Samuel R Saks,
  Director
• Patrick P Grace,
  Director
• Bruce Daugherty,
  See Remarks
• Stuart Davidson,
  Director
• Donald J Kellerman,
  See Remarks
• Leland Gershell,
  CFO and Treasurer
• Carolyn E. Taylor,
  Director
• Richard Newcomb Stillwell,
  Director